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In vitro data suggest that a subgroup of NLR
proteins, including NLRP12, inhibits the transcription
factor NF-kB, although physiologic and disease-rele-
vant evidence is largely missing. Dysregulated
NF-kB activity is associated with colonic inflamma-
tion and cancer, and we found Nlrp12/ mice were
highly susceptible to colitis and colitis-associated
colon cancer. Polyps isolated from Nlrp12/ mice
showed elevated noncanonical NF-kB activation
and increased expression of target genes that were
associated with cancer, including Cxcl13 and
Cxcl12. NLRP12 negatively regulated ERK and AKT
signaling pathways in affected tumor tissues. Both
hematopoietic- and nonhematopoietic-derived
NLRP12 contributed to inflammation, but the latter
dominantly contributed to tumorigenesis. The non-
canonical NF-kB pathway was regulated upon
degradation of TRAF3 and activation of NIK.
NLRP12 interacted with both NIK and TRAF3, and
Nlrp12/ cells have constitutively elevated NIK,
p100 processing to p52 and reduced TRAF3. Thus,
NLRP12 is a checkpoint of noncanonical NF-kB,
inflammation, and tumorigenesis.
INTRODUCTION
The nucleotide-binding domain and leucine-rich-repeat contain-
ing (NLR) family of genes have been largely characterized as acti-
vators of inflammation. For example, NLRP3, NLRC4, NAIP5,
and NLRP6 are essential for inflammasome activation, and
NOD1 and NOD2 are activators of NF-kB and MAPK transcrip-
tion factors. Human diseases that are genetically associated
with NLRs support the immune-activating function of these742 Immunity 36, 742–754, April 20, 2012 ª2012 Elsevier Inc.proteins. Although several additional NLR proteins have been
characterized in vitro, the in vivo functions for the majority of
NLRs remain to be elucidated. Recently, several reports have re-
vealed NLRs that negatively regulate immune activation (Allen
et al., 2011; Xia et al., 2011). However, the in vivo relevance asso-
ciated with the activities of these NLRs is not well defined.
In vitro analysis of NLRP12 (Monarch) (Wang et al., 2002) in
human monocytic cell lines suggests that it is a negative regula-
tory protein that suppresses noncanonical NF-kB activation and
p52-dependent chemokine expression (Lich et al., 2007). It also
has an effect on canonical NF-kB signaling (Williams et al., 2005),
but this effect was modest when RNA interference was used to
reduce its expression (Lich et al., 2007). The attenuation of the
noncanonical pathway is probably through its ability to associate
with NF-kB inducing kinase (NIK), which induces proteasome-
dependent degradation of NIK (Lich et al., 2007). Members of
the canonical and noncanonical NF-kB family play critical roles
in regulating inflammatory and immune responses. NF-kB exists
in the cytoplasm in an inactive form held in check by the inhibitor
IkB. Proteasome-mediated degradation of IkB is linked to its
phosphorylation by the IkB kinase (IKK) complex, IKKa-IKK-
b-IKKg (NEMO). Polyubiquitination and degradation of IkB is
initiated by its phosphorylation, which results in the release
and nuclear translocation of NF-kB to activate various target
inflammatory chemokines, cytokines, and cell surface proteins.
Although in vitro studies in human cell lines have found an
important role for NLRP12 as an inhibitor of NF-kB signaling,
the physiological evidence is lacking. We tested the function of
NLRP12 in gastrointestinal disease, given that activated NF-kB
is routinely observed in colonic mucosal tissues from patients
suffering from inflammatory bowel diseases (IBDs) and dysfunc-
tional NF-kB signaling pathways underlie a diverse range of
gastrointestinal diseases. Aberrant noncanonical NF-kB
signaling and NIK stabilization have also been found in various
cancers (Annunziata et al., 2007; Keats et al., 2007). In addition
to dysfunctional NF- kB signaling, polymorphisms in NLRP12
are associated with a spectrum of inflammatory disorders in
human populations (Je´ru et al., 2008). Although the cause of
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accepted that defects in the intestinal epithelial cell barrier, dys-
regulated host immune responses, and the enteric microflora are
significant factors in colitis and colitis-associated colon cancer
(CAC) (Rakoff-Nahoum et al., 2004).
Here, we demonstrate that Nlrp12/ mice were highly
susceptible to gastrointestinal inflammation and CAC and
showed elevated noncanonical NF-kB signaling. The increase
in tumorigenesis was associated with increased NIK-regulated
genes that have been associated with cancer (Cxcl12 and
Cxcl13) and multiple signaling pathways associated with cancer
in the colons of Nlrp12/ animals. Together, these data impli-
cate NLRP12 as a critical checkpoint during inflammation and
tumorigenesis.
RESULTS
NLRP12 Attenuates Experimental Colitis and Colonic
NIK Expression
Previous in vitro studies have shown that NLRP12 functions as
a negative regulator of noncanonical NF-kB signaling through
inhibition of NIK while the effects on the canonical NF-kB
pathway were modest (Lich et al., 2007). The NF-kB family
members are regulators of chronic inflammation in the colon
and aberrant noncanonical NF-kB signaling and NIK stabilization
has been associated with various cancers (Annunziata et al.,
2007; Keats et al., 2007). Thus, we sought to determine the effect
of NLRP12 deficiency on the development of experimental colitis
(EC) in mice. Wild-type and Nlrp12/ mice were initially chal-
lenged in an acute ECmodel utilizing 5% dextran sulfate sodium
(DSS) for 5 days, and survival was assessed for 14 days. By day
6, 67% of the Nlrp12/ mice reached a moribund state that
required euthanization and by day 10 all of the Nlrp12/ mice
required euthanization (Figure 1A). This was accompanied by
dramatic weight loss among Nlrp12/mice (Figure 1B). Weight
loss measurements were halted on day 6 as a result of increased
morbidity in the Nlrp12/ animals (Figures 1A and 1B). Prior to
euthanasia, the clinical parameters that are typically associated
with disease progression (weight loss, stool consistency, and
rectal bleeding) were assessed with a semiquantitative scoring
system to generate clinical scores (Siegmund et al., 2001).
Nlrp12/ mice presented with significantly increased clinical
severity compared with the wild-type animals (Figure 1C). These
data indicate that NLRP12 serves a protective role during the
progression of acute EC. To assess the impact of Nlrp12 loss
on NF-kB activity, p65, IkBa, NIK, and p52 expression were as-
sayed in ex vivo colons from Nlrp12/ and wild-type mice over
the course of the acute EC model. Although we routinely
observed subtle mouse-to-mouse differences between the
amounts of each of these proteins, in general, we did not observe
consistent differences in either pIkBa or pp65 amounts in
Nlrp12/ mice compared to wild-type (Figure 1D, top panel).
However, NIK and p52 expression was considerably increased
under naive conditions (day 0) and 9 days after the initiation of
the acute DSS challenge in the Nlrp12/ mice (Figure 1D,
bottom panel). Despite the fact that detection of colonic NIK
by was technically challenging, it was elevated in 63% of
Nlrp12/ colons (n = 19) compared to controls. In addition to
directly assessing NF-kB pathway components, we also evalu-ated the amounts of IL-1b and TNF-a, which are commonly
associatedwith EC and canonical NF-kB signaling.We observed
modest differences that did not achieve statistical significance in
the Nlrp12/ and control mice 9 days after the initiation of EC
(Figure 1E). It is unlikely that the subtle differences in these cyto-
kines could result in the robust EC susceptibility of the Nlrp12/
mice. Together, these data suggest that elevated noncanonical
NF-kB activity is correlated with increased susceptibility of the
Nlrp12/ mice in the acute colitis model.
We next assessed the role of NLRP12 in a recurring colitis
model, which required three rounds of DSS treatment (2.5%)
over 60 days (Neufert et al., 2007). Increased weight loss was
observed in all DSS-treated mice. After the first round of DSS
treatment, Nlrp12/ animals exhibited significantly greater
weight loss (Figure 1F), which is consistent with the early weight
loss observed in the acute model. Both strains recovered after
this initial decrease and no other significant differences in weight
loss were observed during subsequent DSS administrations.
During colitis, shortened colon length is correlated with disease
severity. Truncated colons were observed in all DSS-treated
mice, but Nlrp12/ colons were significantly shorter than
controls (Figure 1G). Disease progression was initially examined
via high resolution endoscopy. At the 6 week time point, there
was substantially increased inflammation and bleeding in the
DSS treated Nlrp12/ mice (Figure 1H). This was confirmed
through histopathology after the completion of the model.
Nlrp12/ mice demonstrated significantly increased distal
colon inflammation compared to controls (Figure 1I). Inflamma-
tion in the Nlrp12/ mice was characterized by diffuse and
coalescing mucosal inflammation with multifocal submucosal
extensions that included some follicle formation. The inflamma-
tion in controls was characterized as small multifocal areas of
leukocyte accumulation, which were significantly less severe
than the lesions in Nlrp12/ animals. These data show that
NLRP12 functions as a negative in vivo regulator of inflammation
during recurring colitis.
Nlrp12–/– Cells Display Enhanced Noncanonical NF-kB
Signaling and MAPK Activation
Previously, NLRP12 was shown to attenuate the noncanonical
NF-kB pathway through interactions with NIK in human macro-
phage cell lines (Lich et al., 2007). The data in Figure 1 also
showed enhanced noncanonical NF-kB activation in the colon.
To further explore the physiologic regulation of NIK by
NLRP12, we investigated primary cells isolated from Nlrp12/
mice. We chose to evaluate NLRP12 activity in myeloid dendritic
cells on the basis of data that found the highest Nlrp12 expres-
sion in this cell type (Arthur et al., 2010). To evaluate the
ex vivo contribution of NLRP12 in noncanonical NF-kB signaling,
we stimulated dendritic cells with TNF-a as described by others
(Madge and May, 2010). In wild-type cells, NIK increased during
the first 2 hr after TNFa stimulation and was not detected 5 hr
after stimulation. However, in Nlrp12/ cells, there was a sus-
tained increase in NIK expression over the 18 hr TNF-a stimula-
tion (Figure 2A). NIK activation results in the degradation of p100
into p52 and Nlrp12/ cells displayed increased p100 cleavage
to p52 in the cytosol (Figures 2B and 2C). In addition to increased
NIK activity, we also detected modest increases of p65 and IkBa
in Nlrp12/ dendritic cells. The ratio of pp65 to p65 was notImmunity 36, 742–754, April 20, 2012 ª2012 Elsevier Inc. 743
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Figure 1. NLRP12 Attenuates the Development of Experimental Colitis
(A–E) Wild-type and Nlrp12/mice were challenged with 5% dextran sulfate sodium (DSS) for 5 days and disease progression was assessed daily. WT mock,
n = 4; DSS-treated WT, n = 10; Nlrp12/, n = 8.
(A and B) Survival (A) and weight loss (B) inNlrp12/ and wild-type mice. Because of increasedmortality in theNlrp12/mice, weight assessments were halted
on day 6.
(C) Composite clinical scores reflecting weight loss, stool consistency, and the presence of blood in the stool and/or rectum.
(D) pIkBa, pp65, and NIK levels were evaluated in colons harvested from wild-type and Nlrp12/ mice (two individual mice are shown per time point and all
samples were run together on the same gel) prior to the initiation of acute colitis (day 0) and 9 days after colitis initiation.
(E) Colon amounts of IL-1b and TNFa were assessed by ELISA from organ culture supernatants.
(F–I) Mice were treated with three rounds of 2.5%DSS for 5 days; this treatment was followed by 2 weeks of recovery to assess recurring colitis. WTmock, n = 9;
DSS-treated WT, n = 16; Nlrp12/, n = 8. Data shown are representative of at least three independent experiments and depict the mean ± SEM. The symbols
* and ** indicate p < 0.05 and p < 0.01, respectively, between the DSS-treated WT and Nlrp12/ mice.
(F) Weight loss was assessed throughout the recurring DSS model.
(G) Colon length from Nlrp12/ and wild-type mice.
(H) Disease progression was assessed immediately prior to the third round of DSS (day 37) via high-resolution endoscopy. High-resolution endoscopy was
performed on three animals from each group. Histopathology revealed a considerable amount of crypt loss and immune cell infiltration in Nlrp12/ mice
compared to wild-type mice.
(I) Histopathology scoring revealed a significant increase in distal colon inflammation in the DSS-treated Nlrp12/ mice compared to the wild-type animals.
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NLRP12 Suppresses Colitis-Associated Cancerincreased in Nlrp12/ versus wild-type cells, although the total
level of pp65 is increased in the former because of increased p65
expression. The ratio of pIkba to IkBa was increased, indicating
an effect of NLRP12on the canonical NF-kBpathway (Figure 2D).
However, an extensive analysis of cytokine production from the
wild-type and Nlrp12/ cells showed that most cytokines typi-
cally associated with canonical NF-kB signaling were not
changed (Figures S1A–S1C available online), agreeing with the
modest alteration of canonical NF-kB.744 Immunity 36, 742–754, April 20, 2012 ª2012 Elsevier Inc.In addition to evaluating NF-kB, we also evaluated compo-
nents of the MAPK pathway that have been previously associ-
ated with colitis and colitis-associated cancer (CAC). After
Pam3Cys4 stimulation, the phosphorylation of JNK and p38
occurred at similar amounts in wild-type and Nlrp12/ cells. A
modest, but consistent increase in ERK1 and ERK2 phosphory-
lation was observed in the Nlrp12/ cells compared with the
wild-type regardless of stimulation (Figure 2E). To expand
upon these findings, we utilized a semiquantitative ELISA assay
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Figure 2. Immune Cells Isolated from Nlrp12–/– Mice Have Increased Noncanonical NF-kB Signaling and MAPK Activation
(A) Bone marrow-derived dendritic cells were isolated from wild-type and Nlrp12/ mice. After stimulation with TNF-a, NIK levels steadily increased over the
18 hr time course in Nlrp12/ cells compared to controls.
(B) Increased levels of p100 cleavage to p52 were observed in Nlrp12/ cells over duration of the TNF-a challenge.
(C) Cells were pretreated with Pam3Cys4 and stimulated with CD40L. Under these conditions, we detected increased p52 levels in the cytosolic fraction in cells
isolated from Nlrp12/ mice.
(D) pp65 and pIkBa levels were evaluated in dendritic cells from wild-type and Nlrp12/ mice after Pam3Cys4 and CD40L stimulation.
(E) Pam3Cys4 induced the phosphorylation of JNK and p38 in wild-type and Nlrp12/ cells; however, no considerable differences were consistently observed
between the two genotypes. A modest increase in the phosphorylation of ERK1/2 was observed in the Nlrp12/ cells.
(F) ERK1/2 and pERK were evaluated by ELISA after Pam3Cys4 stimulation for 18 hr and CD40 stimulation over the time course shown. Primary dendritic cells
from five independent animals were cultured and pooled for generating the ELISA data. All data shown are representative of at least three independent
experiments.
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NLRP12 Suppresses Colitis-Associated Cancerto evaluate total ERK1 and 2 and pERK after overnight stimula-
tion with Pam3Cys4 followed by CD40 stimulation over
a 40 min time course. We observed a statistically significant
increase in both ERK1 and 2 and pERK1 and 2 after overnightPam3Cys4 stimulation (Figure 2F). The added CD40 stimulation
did not augment and actually reduced the difference between
control and Nlrp12/ cells. Together, these data confirm that
NF-kB, though predominately noncanonical NF-kB, and ERKImmunity 36, 742–754, April 20, 2012 ª2012 Elsevier Inc. 745
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Figure 3. NLRP12 Interacts with and Maintains TRAF3 Levels
(A) Coimmunoprecipitation of NLRP12 and NIK after cotransfection in HEK293T cells of Fg-NLRP12 and untagged NIK.
(B) NOD2 did not coimmunoprecipitate with NIK after co-transfection.
(C) Bioinformatics identified multiple TRAF2/3 binding motifs in human (Hs) and murine (Mm) NLRP12.
(D) NLRP12 coimmunoprecipitated with TRAF3 after 18hr Pam3Cys4 stimulation in HEK293T cells.
(E) NLRP12 did not coimmunoprecipitate with IKKa after overexpression.
(F) Levels of TRAF3 and TRAF6 were evaluated by immunoblotting after Pam3Cys4 and CD40 stimulation in dendritic cells isolated from wild-type andNlrp12/
mice. All data shown are representative of at least three independent experiments.
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NLRP12 Suppresses Colitis-Associated Cancerpathways are hyperactivated in primary cells isolated from
Nlrp12/ mice.
NLRP12 Functionally Interacts with TRAF3
Previously we showed that NLRP12 can associate with NIK
leading to its degradation (Lich et al., 2007). This association
was confirmed here with FLAG-tagged NLRP12 (Fg-NLRP12),
which coimmunoprecipiated with NIK (Figure 3A). However,
another cytoplasmic NLR, NOD2, did not coimmunoprecipiate
(Figure 3B). In addition to NIK, we also assessed the interaction
between NLRP12 and additional proteins that are important in
the noncanonical NF-kB pathway (Razani et al., 2010). Using
a bioinformatics approach, we identified multiple TRAF binding
motifs in both human and mouse NLRP12 (Figure 3C). Previous
work has shown that in the TRAF2-TRAF3-CIAP1-CIAP2
complex, TRAF3 is the only molecule that directly interacts
with NIK, in which it induces NIK degradation. Indeed, Traf3/
cells show increased noncanonical NF-kB activation (Sun,
2011). NLRP12 was found to interact with endogenous TRAF3
after overnight stimulation with Pam3Cys4 (Figure 3D). It did
not interact with IKKa, which mediates an alternate pathway
that regulates NIK stability (Figure 3E) (Razani et al., 2010). We
next assessed the effect of NLRP12 on TRAF3 in primary
dendritic cells from Nlrp12/ and wild-type mice that were
primed with Pam3Cys4 for 18 hr and stimulated with CD40L.
TRAF3 levels were constitutively decreased in cells isolated
from Nlrp12/ mice compared to controls and remained746 Immunity 36, 742–754, April 20, 2012 ª2012 Elsevier Inc.reduced throughout stimulation (Figure 3F). These findings are
consistent with several reports that showed that TRAF3 degra-
dation preceded NIK stabilization and p100 processing following
engagement of CD40 (Sun, 2011;Vallabhapurapu et al., 2008). In
contrast, the amount of TRAF6 in Nlrp12/ and control cells
were similar (Figure 3F). Together, our data suggests that
NLRP12 maintains the amount of TRAF3, which normally keeps
noncanonical NF-kB activation in check.
NLRP12 Attenuates Disease Progression during CAC
We next evaluated the role of NLRP12 in the initiation and
progression of inflammation driven CAC. Nlrp12/ mice were
subjected to an azoxymethane (AOM) + DSS inflammation-
driven colon tumorigenesis model (Figure 4A). The carcinogen
AOM administered at day 1 induces tumorigenesis (Neufert
et al., 2007). AOM+DSS-treated Nlrp12/ mice showed
increased weight loss compared to controls after the initial and
third round of DSS (Figure 4B). Likewise, AOM+DSS-treated
Nlrp12/ mice showed significantly increased clinical features
during disease progression (Figure 4C). Consistent with the
increased morbidity, colons harvested from AOM+DSS-treated
Nlrp12/ mice were significantly shortened (Figure 4D).
A diverse range of proinflammatory cytokines and chemokines
are increased during IBD andCAC. To evaluate cytokine produc-
tion, we generated organ cultures from colons harvested from
mice that had completed the CAC model. We observed a signif-
icant increase in IL-1b and TNF-a levels by ELISA in the organ
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Figure 4. Nlrp12–/– Mice Are More Susceptible to Inflammation-Driven Colon Tumorigenesis
(A) Schematic of the inflammation-driven colon tumorigenesis model. Wild-type and Nlrp12/mice received a single injection of AOM immediately prior to the
first DSS administration. The mice were then treated with three rounds of 2.5% DSS for 5 days; the treatment was followed by 2 weeks of recovery.
(B) Weight loss was monitored throughout the AOM+DSS model.
(C) Composite clinical scores reflecting weight loss, stool consistency, and the presence of blood in the stool and/or rectum.
(D) Colons removed from AOM+DSS-treated Nlrp12/ mice were significantly truncated compared to similarly treated wild-type mice.
(A–D) WT mock, n = 4; Mock/DSS WT, n = 4; AOM/Mock WT, n = 11; AOM+DSS Nlrp12/, n = 10; AOM+DSS WT, n = 22.
(E) Organ cultures were generated so that the levels of IL-1b and TNF-a in the colon could be determined. WTmock, n = 4; AOM+DSSNlrp12/, n = 6; AOM+DSS
WT, n = 13. For all experiments, data shown are representative of at least three independent experiments and depict the mean ± SEM. Asterisks and pound signs
indicate p < 0.05 between the AOM+DSS- and DSS only-treated WT mice and the AOM+DSS-treated Nlrp12/ mice, respectively.
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NLRP12 Suppresses Colitis-Associated Cancerculture supernatants derived from AOM+DSS-treated Nlrp12/
animals (Figure 4E). These data are consistent with the increased
inflammation observed in the Nlrp12/ mice.
NLRP12 Attenuates Tumorigenesis during CAC
Nlrp12/mice showedmarkedly increased colon inflammation,
proinflammatory cytokine production, and NIK levels during EC.
Previous studies have found that each of these observations is
highly correlated with colon tumorigenesis (Sun, 2011). In vivo
tumorigenesis was assessed during week 6 of the AOM+DSS
model with high-resolution endoscopy, and increased inflamma-tion and extravasation were found in Nlrp12/ mice compared
to controls (Figure 5A). Likewise, the addition of AOM resulted
in increased polyps in Nlrp12/ mice (Figure 5A). After the
completion of the CAC model, we observed macroscopic colon
polyps in the distal colons from the majority of AOM+DSS-
treated mice (Figure 5B). The number and maximal cross-
sectional area of macroscopic polyps were greatly increased in
Nlrp12/ mice compared to controls (Figure 5C). In this model,
the histologic activity index (HAI) is a composite score of indi-
vidual assessments of inflammation, crypt atrophy, hyperplasia,
dysplasia, and the area involved in disease in the mid and distalImmunity 36, 742–754, April 20, 2012 ª2012 Elsevier Inc. 747
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Figure 5. NLRP12 Attenuates Tumorigenesis during CAC
(A) Disease progression was assessed immediately prior to the third round of DSS (day 37) via high-resolution endoscopy. Excessive inflammation and
hemorrhaging was observed in the Nlrp12/ mice. Arrows denote polyp formation in the Nlrp12/ mice. High-resolution endoscopy was performed on three
animals from each group.
(B) Macroscopic polyps (arrows) were identified in the distal and mid colons harvested from Nlrp12/ and wild-type animals.
(C) The number and maximal cross-sectional area of macroscopic polyps was quantified. AOM/Mock WT, n = 11; AOM+DSS Nlrp12/, n = 10; AOM+DSS WT,
n = 22.
(D) Histopathologic activity index (HAI) score in colons harvested after the completion of the CAC model.
(E) Histopathology analysis of colon inflammation, area associated with disease, hyperplasia, and dysplasia in the AOM+DSS-treatedNlrp12/mice. WTmock,
n = 5; Mock/DSS WT, n = 3; AOM/Mock WT, n = 3; AOM+DSS Nlrp12/, n = 5; AOM+DSS WT, n = 15. For all experiments, data shown are representative of at
least three independent experiments and depict the mean ± SEM. *p < 0.05 and **p < 0.01, between the AOM+DSS-treated WT mice and Nlrp12/ mice.
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NLRP12 Suppresses Colitis-Associated Cancercolon (Meira et al., 2008). AOM+DSS-treated Nlrp12/ mice
had significantly enhancedHAI compared to controls (Figure 5D),
substantiated by a significant increase in inflammation, hyper-
plasia, and dysplasia with a greater affected area in Nlrp12/
mice compared to control mice (Figure 5E). Some of these
lesions were further characterized as adenocarcinomas in the
Nlrp12/ mice.748 Immunity 36, 742–754, April 20, 2012 ª2012 Elsevier Inc.The Pathogenesis inNlrp12–/– Mice Is Derived fromBoth
Hematopoietic and Nonhematopoietic Sources
Colon tumorigenesis is correlated with intestinal inflammation.
Gastrointestinal tumors typically originate from dysplastic
epithelial or stem cells and are infiltrated by a variety of lymphoid
andmyeloid cell types that can potentiate neoplastic transforma-
tion and tumorigenesis (Murdoch et al., 2008). To determine the
Immunity
NLRP12 Suppresses Colitis-Associated Cancerrelevant cell compartment responsible for the gastrointestinal
inflammation and tumorigenesis in the Nlrp12/ animals, we
generated wild-type and Nlrp12/ chimeric mice with adoptive
bonemarrow transplantation. After a 6week reconstitutionphase
to achieve near-complete chimerism (Figure S2A), these animals
were subjected to AOM+DSS. Bone marrow chimerism did not
affect the phenotypic outcome, in that Nlrp12/ mice that did
(Nlrp12//Nlrp12/) or did not receive Nlrp12/ bone
marrow showed greater increases in weight loss compared to
wild-type mice that did (WT/WT) or did not receive wild-type
bone marrow grafts (Figures S2B–S2E). Among bone marrow
recipients that were treated with AOM+DSS, two trends were
observed. After the first round of DSS, Nlrp12/ mice that
received wild-type bone marrow (WT/ Nlrp12/) and wild-
type mice that received Nlrp12/ bone marrow (Nlrp12//
WT) showed similar weight loss as Nlrp12//Nlrp12/ mice,
and all three had significantly more weight loss than WT/WT
mice (Figure 6A). This suggests that during this phase, NLRP12
in both the hematopoietic and nonhematopoietic compartment
contributed to disease outcome. During the second round of
DSS, we observed significant weight loss in the WT/ Nlrp12/
mice, but not theNlrp12//WTmice, indicating that during the
later stages of this model, the effect of NLRP12 was primarily
attributed to the nonhematopoietic compartment (Figure 6A).
More detailed HAI scores at the later time point revealed that
Nlrp12//Nlrp12/ mice and WT/ Nlrp12/ chimeric
mice demonstrated a significantly increased histopathology
compared to the WT/WT mice and Nlrp12//WT mice (Fig-
ure 6B). The increased HAI scores were associated with a signif-
icant increase in colon hyperplasia, dysplasia, and area affected,
whereas differences in inflammation were not statistically signif-
icant (Figure 6C). A similar pattern was observed with epithelial
defects characterized by extensive epithelial tattering, large
eroded areas, and extensive ulcerations throughout the mid
and distal colon (Figures 6D and 6E). Similar to the nonchimeric
mice, Nlrp12//Nlrp12/ and WT/Nlrp12/ mice had
significantly increased numbers of macroscopic polyps
compared to WT/WT and Nlrp12//WT animals (Figure 6F).
These results indicate that nonhematopoietic NLRP12 affected
tumor outcome. Thus, we evaluated NLRP12 expression in the
mouse gastrointestinal system by using a publically accessible
microarray meta-analysis search engine (http://www.nextbio.
com/b/search/ba.nb) as described (Kupershmidt et al., 2010).
NLRP12 was found in the gastrointestinal system, including
intestinal epithelial cells and the colon (Figure S3A). These data
suggest an early role forNLRP12 in theAOM+DSSmodel through
both hematopoietic and nonhematopoietic compartments.
Later, coincidental with polyp formation, the effect of NLRP12
is derived primarily from the nonhematopoietic compartment.
These findings are consistent with the current paradigm, which
suggests that intestinal epithelial cell (IEC)-derived NF-kB can
influence the incidence of colonic tumor, whereas immune-
derived NF-kB contributes to inflammation during the early
stages of tumorigenesis (Karrasch and Jobin, 2008).
NLRP12 Attenuates Multiple Pathways Associated
with Colon Tumorigenesis
Previous in vitro studies identified twochemokines,CXCL12 (also
known as SDF-1) and CXCL13 (also known as BLC), which areknown tobe regulatedby noncanonical NF-kBactivation (Bonizzi
et al., 2004) and by NLRP12 in cell lines (Lich et al., 2007). Both of
these chemokines have been shown to be highly upregulated in
various types of human cancers (Del Grosso et al., 2011; Fushimi
et al., 2006;Wharry et al., 2009).Weevaluated theexpressionand
protein levels of CXCL12 and CXCL13 in colon samples after
either chronic EC or CAC and observed robust increases in their
expression in Nlrp12/ colons after completion of the AOM+
DSS treatment (Figure 7A). CXCL12 protein was difficult to
detect (data not shown); however, CXCL13 protein was
increased >383 in Nlrp12/ colons over controls (Figure 7B).
This increase was only observed in the context of cancer, given
that neither untreated mice nor mice subjected to chronic DSS
showed this difference. These data are consistent with the
model that the unchecked noncanonical NF-kB activation in
Nlrp12/ mice led to elevated CXCL12 and CXCL13, which
are associated with several cancers. It is worth mentioning that
in Figure S1B, CXCL12 was not detected in primary dendritic
cells. However, this was not unexpected because CXCL12 is
predominately expressed by stromal cells and functions in den-
dritic cell recruitment during tumorigenesis (Orimo et al., 2005).
To further evaluate specific genes that are upregulated during
colon tumorigenesis, we performed expression profiling of
a large subset of cancer-associated genes in macroscopic
polyps microdissected from Nlrp12/ and wild-type mice.
There were >3-fold increase of nine genes, including Akt1 and
Jun, and a greater than 2-fold increase in an additional five genes
in polyps isolated from Nlrp12/ relative to controls (Figure 7C).
Select genes were subsequently verified with nonmultiplexed
real-time PCR on whole-colon tissues isolated from individual
mice (Figure 7D). Akt, Jun, and Nr3c1 associated with the hyper-
activation of cancer pathways were significantly upregulated in
the polyps and colons from Nlrp12/ mice. We also found
genes that were not significantly upregulated, including Nik,
Ptgs1 (Cox1), and Ptgs2 (Cox2), but Relb and Nfkb2 transcripts
which encode the noncanonical NFkB proteins were increased
moderately (Figure S4).
In addition to the activation of NF-kB, previous studies have
shown that the NOD1 and NOD2 have the ability to modulate
MAPK signaling pathways (Kobayashi et al., 2005; Park et al.,
2007). Our in vitro data also suggest an effect of NLRP12 on
MAPK. Further, noncanonical NF-kB can induce MAPK activa-
tion (Dhawan and Richmond, 2002). Thus, we evaluated ERK
phosphorylation by immunohistochemistry and observed
increased pERK staining in colon epithelial cells lining the tops
of the crypts and in goblet cells, in keeping with both EC and
CAC models (Figure 7E; Figure S4E). However, Nlrp12/ colon
showed robust staining compared to wild-type colons, with clear
staining observed throughout the crypts (Figure 7E; Figure S4E).
Colon sections were digitally imaged and ERK staining was eval-
uated with ImageJ software, which confirmed a significant
increase in pERK in Nlrp12/ colons (Figure 7F). These data
support the in vitro data in Figure 2 and indicates that NLRP12
serves as a checkpoint for enhanced ERK activation during CAC.
DISCUSSION
Both the canonical and noncanonical NF-kB pathways exert
wide-ranging effects on immune regulation, cell proliferation,Immunity 36, 742–754, April 20, 2012 ª2012 Elsevier Inc. 749
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Figure 6. NLRP12 Mediates the Development of CAC through a Nonhematopoietic Cellular Compartment
(A) Weight change of indicated bone marrow chimera mice.
(B) Composite HAI score.
(C) Colon hyperplasia, dysplasia, and area involved in disease and inflammation were each individually scored.
(D) Nlrp12/ mice receiving wild-type or Nlrp12/ bone marrow demonstrated a significant increase in colon area affected by disease and defects to the
epithelial layer of the colon.
(E) Representative histopathology emphasizing defects in the epithelial layer for each group indicated. WT/WT and Nlrp12//WT shows mild to moderate
surface layer thinning and tattering. WT/Nlrp12/ andNlrp12//Nlrp12/ showsmoderate to severe surface layer attenuation and erosions with multifocal
detachments of epithelial islands.
(F) The average number of macroscopic polyps observed in the colon. For all experiments, data shown are representative of three independent experiments and
depict the mean ± SEM. Asterisks and pound signs indicate p < 0.05 between the indicated groups. WT/WT, n = 5; Nlrp12//WT, n = 7; WT/ Nlrp12/,
n = 7; Nlrp12//Nlrp12/ n = 3.
Immunity
NLRP12 Suppresses Colitis-Associated Cancerand cell death. Because chronic inflammation and the develop-
ment of cancer are intimately linked in gastrointestinal disease,
extensive research has been focused on dissecting the role of
NF-kB and modifiers of NF-kB activity associated with these750 Immunity 36, 742–754, April 20, 2012 ª2012 Elsevier Inc.two diverse biological processes. A recent publication by Zaki
et al. (2011) suggested the increased inflammation and tumori-
genesis observed in the Nlrp12/ mice was associated with
increased canonical NF-kB signaling. Consistent with these
Immunity
NLRP12 Suppresses Colitis-Associated Cancerfindings, we also detected a subtle increase in pp65 and pIkBa
in vitro. However, our data suggest that NLRP12 is a robust
negative regulator of noncanonical NF-kB signaling both in
culture and in animals, accompanied by ERK activation and
induction of NIK-dependent genes, such as CXCL12 and
CXCL13, that are associated with tumorigenesis during
gastrointestinal inflammation. It is possible that NLRP12 may
indirectly mediate canonical NF-kB signaling through the nonca-
nonical pathway. This hypothesis is supported by previous
data, which demonstrated that the noncanonical NF-kBpathway
can influence canonical NF-kB signaling through IKKa- and
TRAF3-dependent mechanisms (Adli et al., 2010; Zarnegar
et al., 2008).
In addition to NLRP12, other NLRs have been found to influ-
ence the development of colitis and CAC. In humans, mutations
in NOD1, NOD2, and NLRP3 have each been shown to
contribute to the development of IBD, with NOD2 having the
strongest correlation to Crohn’s disease. However, the exact
mechanism by which NOD2 affects IBD and CAC remains to
be fully elucidated (Sollid and Johansen, 2008). NOD1 and
NLRP3 have a significant protective role in mediating EC and
CAC in animals (Allen et al., 2010; Chen et al., 2008; Zaki et al.,
2010). In both Nod2/ and Nod1/ mice, EC and CAC were
attenuated after broad spectrum antibiotic treatment, impli-
cating a role for the gut microbiota (Chen et al., 2008). Nlrp3/
mice are also more sensitive to DSS-induced experimental
colitis and AOM+DSS-induced CAC (Allen et al., 2010; Zaki
et al., 2010). In mice lacking the NLR inflammasome adaptor
Pycard (also known as ASC), the mechanism is more clearly
attributed to the lack of IL-18 (Dupaul-Chicoine et al., 2010;Sal-
cedo et al., 2010; Zaki et al., 2010).
Inflammation is a dynamic process that requires molecular
brakes or checkpoints to prevent an overwhelming response
that can result in damage to the host. Although several reports
suggest that some NLRs function to attenuate inflammation,
this idea has yet to gain traction because in vivo evidence has
been lacking (Ting et al., 2010). In the present study, cells and
colons from Nlrp12/ mice have enhanced activation of
NF-kB, most robustly in the noncanonical NF-kB pathway and
this is consistent with more severe EC and CAC. Activation of
the canonical pathway is more moderate and showed a great
degree of variation between animals. The ability of NLRP12 to
interact with NIK and attenuate the generation of p52 is of partic-
ular importance in light of recent studies that have implicated
dysregulated noncanonical NF-kB signaling in various cancers.
For example, NIK stabilization is associated with inactivating
mutations in TRAF2, TRAF3, cIAP1, and cIAP2 and has been
extensively characterized in multiple myeloma, whereas gain-
of-function mutations in NIK are associated with this malignancy
(Annunziata et al., 2007; Keats et al., 2007). In addition tomultiple
myeloma, increased levels of NIK have been associated with
several other hematological malignancies and solid tumors
(Thu and Richmond, 2010). While NIK detection is considered
technically challenging, we were able to detect its elevation
in vivo, as well as the elevation of chemokines that have previ-
ously been found to be regulated by the noncanonical NF-kB
pathway and by NLRP12 (Bonizzi et al., 2004). In CAC, we iden-
tified robust amounts of CXCL13 (and Cxlc13 expression) and
increased expression of Cxlc12 in all of the Nlrp12/ mice.These findings are significant as these chemokines are strongly
associated with various types of cancers in human populations,
including colorectal tumorigenesis (Del Grosso et al., 2011;
Fushimi et al., 2006). The finding that these chemokines were
only dysregulated in the CAC model and not the colitis models
further implicates their contribution to the increased tumorigen-
esis observed in the Nlrp12/ mice. In addition to the nonca-
nonical NF-kB pathway, our findings also indicate that NLRP12
directly or indirectly contributes to the hyperactivation of
ERK and cancer-associated signaling pathways, such as Akt
and Jun.
The common hypothesis that inflammation promotes tumori-
genesis is exemplified during the development of CAC. Our
previous analysis of Nlrp12/ mice showed that they have an
attenuated inflammatory response during the development of
contact hypersensitivity, which was associated with a defect in
dendritic cell and neutrophil migration (Arthur et al., 2010).
However, we were not able to define the underlying molecular
mechanism in this previous study. Thus, it is likely that
NLRP12, similar to other NLRs and pathogen recognition
receptor proteins, might display distinct tissue-specific func-
tions. In the context of colitis and CAC, this work shows that
NLRP12 functions as a negative regulator of the NF-kB pathway
through its interaction and regulation of NIK and TRAF3, and as
a checkpoint of critical pathways associated with inflammation
and inflammation-associated tumorigenesis.EXPERIMENTAL PROCEDURES
Experimental Animals
All studies were conducted in accordance with the IACUC guidelines of UNC
Chapel Hill and NIH Guide for the Care and Use of Laboratory Animals.
Nlrp12+/ mice have been described (Arthur et al., 2010). All experiments
were conducted with male mice housed under SPF conditions that were age
matched and backcrossed for at least nine generations onto the C57Bl/6
background.
Induction of Colitis and Inflammation-Driven Tumor Progression
The induction of acute colitis was achieved by exposing the mice to one cycle
of 5% DSS (MP Biomedicals). The induction of recurring colitis was achieved
by exposing the mice to 3 cycles of 2.5% DSS (Neufert et al., 2007). For CAC,
mice were given 1 i.p. injection (10 mg/kg body weight) of the mutagen AOM
(Sigma Aldrich), followed by 3 DSS exposures (2.5%). Mice were sacrificed
and characterized at specific time points throughout the course of the DSS
or AOM+DSS challenge or when the animals were moribund.
Disease progression was determined by body weight changes, the pres-
ence of rectal bleeding and stool consistency. Each parameter was scored
and averaged to generate a semiquantative clinical score, as described (Sieg-
mund et al., 2001). Body weight was assessed at least 5 days per week
throughout the course of the experiment. Stool consistency and rectal
bleeding were each assessed, 1 day and 4 days after each DSS treatment.
We utilized visual inspection and a Hemoccult Immunochemical Fecal Occult
Blood Test (Beckman Coulter) to sample for blood in the stool. Colon length
was measured upon completion of each study.
Endoscopic Tumor Investigation
Tumor growth and progression was evaluated in situ by mini-endoscopy, as
previously described (Uronis et al., 2007) with a Coloview system (Karl Storz
Veterinary Endoscope). The endoscopy was performed 6 weeks after the initi-
ation of the colitis, and colitis-associated cancer models and each session
were digitally recorded. Mice were fasted overnight to avoid fecal matter
obstructions. We preformed real time evaluations of colons (3–4cm) that
included the area from the anal verge to the splenic flexure.Immunity 36, 742–754, April 20, 2012 ª2012 Elsevier Inc. 751
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Figure 7. NLRP12 Attenuates Noncanonical NF-kBRegulated Chemokines, Cancer-Associated Gene Expression and Specific MAPK Family
Members during CAC
(A) Cxcl12 and Cxcl13 gene expression in colons.
(B) Colon levels of CXCL13 were assessed from organ culture supernatants by ELISA.
(A and B) WT mock, n = 5; Mock/DSS WT, n = 3; AOM/Mock WT, n = 3; AOM+DSS Nlrp12/, n = 5; AOM+DSS WT, n = 15.
(C) Macroscopic polyps were removed from wild-type and Nlrp12/ mice and gene expression was assessed with a multiplex gene expression array. Data
shown represent genes that were significantly upregulated, defined as >2-fold increase, in RNA that was pooled from polyps that were microdissected from
Nlrp12/ mice compared to wild-type mice. WT, n = 5; Nlrp12/, n = 5.
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The entire colon was removed, flushed, and opened longitudinally for assess-
ing macroscopic polyp formation as previously described (Allen et al., 2010).
Polyps were identified by a trained investigator with a dissecting microscope
(103 magnification). For histopathology, the colons were Swiss rolled and
fixed in 10% buffered formalin. Paraffin embedded colons were sectioned at
5 mm, processed for H&E staining, and evaluated by an experienced veterinary
pathologist (A.B.R.) whowas blinded to genotype and treatment and scored as
described (Meira et al., 2008).
Colon Organ Culture and Proinflammatory Mediator Assessments
Organ cultures were generated for assessing cytokine levels, as previously
described (Greten et al., 2004). The distal most section of colon was isolated
and cut into 1 cm2 sections. These strips were washed with PBS containing
penicillin and streptomycin, and the wet weight of each section was recorded.
The isolated colon sections were incubated overnight in nonsupplemented
RPMI media containing penicillin and streptomycin. Cell-free supernatants
were harvested and assayed via ELISA.
Immunoblots and NF-kB Assessments from Colon Tissue
The colon tissue was processed into cytosolic and nuclear fractions with the
NE-PER Nuclear and Cytoplasmic Extraction Kit (Thermo Scientific) in accor-
dance with the manufacturer’s instructions. A total of 30 mg of protein from
each sample was separated by SDS-PAGE with 4%–12% NuPAGE Bis-Tris
gels (Invitrogen), transferred, and incubated overnight with the respective anti-
bodies (Supplemental Experimental Procedures).
Expression Profiling
Total RNA was isolated from either polyps or polyp-free adjacent tissue after
the completion of the CACmodel. RNA from polyps isolated from five different
animals for each genotype was pooled together prior to the cDNA reaction.
Pooled samples were analyzed with RT2 Profiler PCR Arrays (SABiosystems)
in accordance with the manufacturer’s protocols or by Taqman rtPCR analysis
(ABI). Array results were confirmed on total RNA isolated from distal colon
sections from individual mice that were exposed to AOM+DSS independently
of those used for array profiling.
Coimmunoprecipitation
Detailed protocols for cell culture, coimmunoprecipitation, and antibodies
used have been previously published (Lich et al., 2007) (Supplemental Exper-
imental Procedures).Wild-type andNlrp12/ dendritic cells were isolated and
cultured under standard conditions. Cells were lysed in 1% RIPA buffer for
immunoblotting. For MAPK activation assessments, primary dendritic cells
were plated and assayedwith a cell-based ERK1/2 ELISA sampler kit (RayBio).
For HEK293T cells, cells were plated and transfected with FuGene 6 (Roche).
For immunoprecipitations, the cell lysates were prepared as previously
described (Williams et al., 2005). All plasmids were used at equal molar
concentrations, unless otherwise stated. Cell lines stably expressing Ha-
Monarch-1 or shRNA targeting Monarch-1 have been described (Lich et al.,
2007; Williams et al., 2005).
Statistical Analysis
All data are presented as the mean ± standard error of the mean (SEM).
Complex data sets were analyzed by analysis of variance (ANOVA) and then
analyzed by either Tukey-Kramer HSD or Newman-Keuls post test for multiple
comparisons. Single data points were assessed by the Student’s two-tailed
t test. The product limit method of Kaplan and Meier was utilized for gener-
ating the survival curves, which were compared by using the log rank test.
A p value that was less than 0.05 was considered statistically significant for
all data sets.(D) Gene expression for Akt1, Jun, and Nr3c1 was used for verifying the array dat
were not assessed on the array. WT mock, n = 3; Nlrp12/ mock, n = 3; WT DS
(E) pERK levels were evaluated by immunohistochemistry from paraffin-embedd
(F) pERK levels were evaluated with semiquantitative histopathology image
AOM+DSS WT, n = 7.SUPPLEMENTAL INFORMATION
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